POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab

Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.1266
https://www.valueinhealthjournal.com/article/S1098-3015(21)03061-8/fulltext
Title : POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)03061-8&doi=10.1016/j.jval.2021.11.1266
First page :
Section Title :
Open access? : No
Section Order : 10803
Categories :
Tags :
Regions :
ViH Article Tags :